Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 1 2Phase 2/3 1Phase 2 1

Status

Completed 3Active not recruiting 2Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 6Carcinoma, Hepatocellular 5Head and Neck Neoplasms 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms, Squamous Cell 2Glioblastoma 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Urinary Incontinence 1Tuberous Sclerosis 1Sarcoma 1Recurrent respiratory papillomatosis 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Postoperative Complications 1Papillomavirus Infections 1Papilloma 1Ovarian Neoplasms 1Orgasm 1Oligodendroglioma 1Neoplasms 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1Medication Adherence 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Laryngeal Neoplasms × Clear all
NCT04129320 2022-02-08

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

MacroGenics

Phase 2/3 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡